Effects of GLP-1 Receptor Polymorphisms on Adolescent Obesity

Effects of GLP-1 Receptor Polymorphisms on Adolescent Obesity

Obesity is becoming a concerning disease in developing countries. Like other multifactorial diseases, genetics plays a substantial role in the development of this disease. We tried to investigate genetic variations (mutation/polymorphism) of GLP-1R gene in children diagnosed with obesity and to ide...

Full description

Bibliographic Details
Main Authors:	Mahafarin Maralani, Tufan Cankaya, Esra Ataman, Yavuz Tokgoz, Erkan Kaytankas, Nur Arslan, Behzad Baradaran, Khalil Hajiasgharzadeh, Ayfer Ulgenalp
Format:	Article
Language:	English
Published:	Tehran University of Medical Sciences 2023-07-01
Series:	Acta Medica Iranica
Subjects:	Glucagon-like peptide-1 Glucagon-like peptide-1 (GLP-1) receptor Single-nucleotide polymorphism Obesity development
Online Access:	https://acta.tums.ac.ir/index.php/acta/article/view/9128

Similar Items

Targeting the GLP-1/GLP-1R axis to treat osteoarthritis: A new opportunity?
by: C. Meurot, et al.
Published: (2022-01-01)

GLP-1 and GLP-2 Orchestrate Intestine Integrity, Gut Microbiota, and Immune System Crosstalk
by: Nyan Abdalqadir, et al.
Published: (2022-10-01)

Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs
by: Sina A. Gharib, et al.
Published: (2024-10-01)

The impact of glucagon-like peptide-1 (GLP-1) agonists in the treatment of eating disorders: a systematic review and meta-analysis
by: Hanieh Radkhah, et al.
Published: (2025-02-01)

Imeglimin enhances glucagon secretion through an indirect mechanism and improves fatty liver in high‐fat, high‐sucrose diet‐fed mice
by: Osamu Kikuchi, et al.
Published: (2024-09-01)

The GLP-1 receptor is expressed in vivo by human metastatic prostate cancer
by: Mark S Stein, et al.
Published: (2024-01-01)

GLP-1 Receptor Agonists: A Promising Therapy for Modern Lifestyle Diseases with Unforeseen Challenges
by: Patrycja Kupnicka, et al.
Published: (2024-11-01)

Evaluation of Glucagon-Like Peptide 1 (GLP-1) Levels and Oxidative Stress in Preterm Infants
by: E Abbasi, et al.
Published: (2022-03-01)

The role of glucagon-like peptide-1 receptor agonists (GLP1-RAs) in the management of the hypertensive patient with metabolic syndrome: a position paper from the Korean society of hypertension
by: Hae Young Lee, et al.
Published: (2024-09-01)

BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy
by: Tina Zimmermann, et al.
Published: (2022-12-01)

Multifaceted Roles of GLP-1 and Its Analogs: A Review on Molecular Mechanisms with a Cardiotherapeutic Perspective
by: Sudhir Pandey, et al.
Published: (2023-06-01)

Glucagon-like peptide-1 receptor agonists in patients treated with antipsychotics
by: A. Delgado, et al.
Published: (2021-04-01)

Current and potential use of GLP-1R agonists: beyond type 2 diabetes
by: Graciela Zambrano-Galván, et al.
Published: (2024-10-01)

The associations of incretin hormone concentration with gestational diabetes mellitus
by: Tatiana V. Saprina, et al.
Published: (2016-05-01)

Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date
by: Howell R, et al.
Published: (2019-04-01)

The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP
by: Jonathan D. Douros, et al.
Published: (2025-02-01)

Incretins role in Latent autoimmune diabetes of adults pathogenesis, the possibility of therapy with combination of glucagon-like peptide-1 agonist (GLP-1) and insulin.
by: Iuliia V. Silko, et al.
Published: (2016-07-01)

GLP-1 analogs in the treatment of obesity
by: Aleksandra Metelska, et al.
Published: (2022-08-01)

Foundational contributions of Svetlana Mojsov to the GLP-1 field
by: George Barany, et al.
Published: (2024-10-01)

Habitual physical activity is associated with lower fasting and greater glucose-induced GLP-1 response in men
by: Charlotte Janus, et al.
Published: (2019-12-01)

The benefits of GLP1 receptors in cardiovascular diseases
by: Lamija Ferhatbegović, et al.
Published: (2023-12-01)

Revolutionizing Diabetes and Obesity Management: A Comprehensive Review of Tirzepatide’s Dual Agonist Approach
by: Sonam Samal, et al.
Published: (2024-04-01)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
by: Seungah Lee, et al.
Published: (2017-03-01)

Relationship between diet/exercise and pharmacotherapy to enhance the GLP‐1 levels in type 2 diabetes
by: Yuki Fujiwara, et al.
Published: (2019-07-01)

GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight
by: Giulia Monti, et al.
Published: (2022-06-01)

Commentary on “Electroacupuncture Inhibited Spinal Glial Activation in Neuropathic Pain via Glucagon-like Peptide 1/Glucagon-like Peptide 1 Receptor Signaling”
by: Hulya Karatas
Published: (2024-09-01)

The protective role of GLP-1 in neuro-ophthalmology
by: Sohum Sheth, et al.
Published: (2023-08-01)

Potential impact of GLP-1 receptor agonists on male fertility: a fable of caution
by: Stefan S. Du Plessis, et al.
Published: (2024-11-01)

The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus
by: Marina Vladimirovna Shestakova
Published: (2010-09-01)

Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review
by: Alorfi NM, et al.
Published: (2022-08-01)

Glucagon-like peptide (GLP)-1 regulation of lipid and lipoprotein metabolism
by: Hoffman Simon, et al.
Published: (2024-08-01)

Frequently asked questions to the 2023 Obesity Medicine Association Position Statement on Compounded Peptides: A call for action
by: Harold Edward Bays, et al.
Published: (2024-09-01)

Potential benefits of GLP-1 analogues and metformin in patients with osteoarthritis
by: Anna Skowronek, et al.
Published: (2025-01-01)

Liraglutide Attenuates Aortic Valve Calcification in a High-Cholesterol-Diet-Induced Experimental Calcific Aortic Valve Disease Model in Apolipoprotein E-Deficient Mice
by: Yangzhao Zhou, et al.
Published: (2023-09-01)

Expression of Glucagon-Like Peptide 1 Receptor during Osteogenic Differentiation of Adipose-Derived Stem Cells
by: Yun Kyung Jeon, et al.
Published: (2014-12-01)

Are obese rats influenced by GLP1 and IR through aerobic exercise? A case study
by: Ali Sayyah, et al.
Published: (2016-08-01)

GLP-1 receptor agonist improves metabolic disease in a pre-clinical model of lipodystrophy
by: Ahlima Roumane, et al.
Published: (2024-04-01)

GLP-1 receptor agonist as an effective treatment for breast cancer-related lymphedema: a case report
by: Fionnuala Crowley, et al.
Published: (2024-04-01)

Immunohistochemical and Morphometrical Studies on the Distribution of Glucagon-like Peptide-1 (GLP-1)-immunoreactive Cells in the Chicken Intestine
by: Kohzy Hiramatsu, et al.
Published: (2005-08-01)

Comparative Study on the Distribution of Glucagon-like Peptide-1 (GLP-1)-immunoreactive Cells in the Intestine of Chicken and Ostrich
by: Kohzy Hiramatsu, et al.
Published: (2003-01-01)